Black Deal 12 months of Premium for €49.99 instead of €74.99 12 months €49.99 instead of €74.99 until Sun, Dec 13
Get the deal

MR_Lysolek - FACEIT level 7, 1,397 ELO

Poland
On FACEIT since 2025 349 matches tracked 28 matches in 30 days
Last updated:

MR_Lysolek at a glance

Level 7 1,397 ELO best map Nuke (60%)
Level 7

Last 20 matches compared with 2,993 players in this group: K/R, ADR and win rate above average.

RatingCalculated with the HLTV Rating 1.0 formula from kills, deaths and multi-kills per round. 1.00 is an average match.
better than 81%
1.12
SpreadHow much the rating swings from match to match. The smaller, the more consistent. ±0.29 ConsistencyShare of matches with a rating of 0.90 or higher. 80%
K/R
0.82
better than 85% of players
Level 7 avg: 0.73
Last 12 months
ADR
87.1
better than 81% of players
Level 7 avg: 79.8
Last 12 months
Win rate
60%
better than 83% of players
Level 7 avg: 50%
Last 12 months

Facts

134 ELO Next goal That is 4 to 5 wins.
5 W · 4 L Best day +9 ELO · Aug 23, 2026
3 W · 5 L Overtime in overtime
Mirage Favorite map 137 of 349 matches
Nuke 60% Map pool tip weakest: Anubis 26%
2 Zeus kills Rare kills 8 knife kills
12:00-18:00 Best time 60% win rate vs. 50%
FormMapsTiming

134 ELO away from level 8. That is 4 to 5 wins. 5:4 on Aug 23, 2026 (+9 ELO, last 90 days). 8 matches in overtime, 3 of them won (last 90 days). Most played: Mirage (137 of 349 matches). Strongest map: Nuke (60% win rate, 40 matches). Weakest: Anubis (26%, 31 matches). 2 Zeus kills and 8 knife kills (last 90 days). Best results between 12:00 and 18:00: 60% win rate vs. 50% overall (73 matches).

About MR_Lysolek

MR_Lysolek plays CS2 on FACEIT level 7 with 1,397 ELO. The stats cover 349 matches. The strongest map is Nuke with a 60% win rate in 40 matches. Most played: Mirage with 137 matches and a 50% win rate. Biggest strength: Rounds with first kill at 15%, better than 96% of level 7 players. Last 20 matches: 12 wins, 8 losses, +30 ELO. MR_Lysolek does best between 12:00 and 18:00: 60% win rate in 73 matches.